SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76831.75
4.03 (-0.01%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Max Healthcare Institute Ltd.	Q V+ PT	1,08,476 Mid Cap	1,129.05 (1.30%)	75.2	10.23	27.27	155.29	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Yatharth Hospital & Trauma Care Services Ltd.	Q V PT	8,132 Small Cap	840.80 (-0.38%)	85.24	5.02	27.90	137.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	3B Blackbio Dx Ltd.	Q V PT	1,112 Small Cap	1,295.05 (0.00%)	22.54	4.07	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Artemis Medicare Services Ltd.	Q V PT	4,408 Small Cap	281 (0.92%)	42.61	5.07	21.41	79.02	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Novartis India Ltd.	Q V+ PT	4,023 Small Cap	1,629.15 (0.00%)	41.14	4.73	-4.06	54.56	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Jupiter Life Line Hospitals Ltd.	Q V PT	10,728 Small Cap	328.85 (0.49%)	56.06	6.67	21.03	54.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Jagsonpal Pharmaceuticals Ltd.	Q V+ PT	1,511 Small Cap	229.20 (0.00%)	35.08	6.36	11.13	39.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Neuland Laboratories Ltd.	Q V+ PT	24,345 Small Cap	18,975.40 (0.00%)	67.05	13.05	16.64	37.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Kwality Pharmaceuticals Ltd.	Q V+ PT	2,815 Small Cap	2,715.05 (0.07%)	41.8	8.47	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Rainbow Childrens Medicare Ltd.	Q V PT	15,076 Small Cap	1,498.15 (0.93%)	60.3	8.95	20.26	35.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Global Health Ltd.	Q V PT	37,844 Small Cap	1,412.60 (0.36%)	76.27	9.41	16.83	34.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Marksans Pharma Ltd.	Q V+ PT	11,941 Small Cap	264.70 (0.46%)	39.71	7.23	22.06	32.86	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Natco Pharma Ltd.	Q V PT	16,606 Small Cap	932.65 (0.59%)	11.71	1.8	18.26	32.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Lupin Ltd.	Q V PT	1,10,189 Mid Cap	2,423.90 (0.58%)	20.66	4.92	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,436 Small Cap	5,041.05 (0.00%)	34.75	7.04	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	Wanbury Ltd.	Q V+ PT	1,157 Small Cap	326.50 (-1.42%)	17.5	8.01	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,27,149 Large Cap	8,922.05 (0.89%)	85.19	12.76	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,382 Small Cap	367.65 (-0.35%)	18.42	4.57	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Vimta Labs Ltd.	Q V+ PT	2,620 Small Cap	589.10 (0.46%)	32.89	5.57	14.27	28.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Poly Medicure Ltd.	Q V PT	17,025 Small Cap	1,679.65 (0.00%)	50.67	5.58	19.91	26.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Rubicon Research Ltd.	Q V+ PT	25,860 Small Cap	1,568 (0.37%)	137.43	19.11	32.49	25.95	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Shalby Ltd.	Q V PT	1,783 Small Cap	165.05 (0.00%)	15.79	1.43	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Gufic Biosciences Ltd.	Q V PT	3,826 Small Cap	381.55 (0.00%)	60.59	5.76	16.69	24.75	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	RPG Life Sciences Ltd.	Q V+ PT	4,827 Small Cap	2,916.15 (-0.08%)	41.91	7.97	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	Syncom Formulations (India) Ltd.	Q V PT	1,240 Small Cap	13.10 (-0.68%)	16.31	3.01	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Caplin Point Laboratories Ltd.	Q V PT	19,939 Small Cap	2,631.10 (0.30%)	31.09	5.56	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Shree Ganesh Remedies Ltd.	Q V PT	822 Small Cap	640.40 (0.00%)	46.26	5.04	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Anthem Biosciences Ltd.	Q V PT	44,516 Mid Cap	798.95 (1.11%)	71.31	13.68	13.62	19.07	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Morepen Laboratories Ltd.	Q V PT	3,101 Small Cap	56.98 (0.69%)	46.94	2.5	14.44	19.03	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	CORONA Remedies Ltd.	Q V+ PT	12,807 Small Cap	2,115 (1.00%)	69.28	17.17	19.49	18.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Fischer Medical	38.57	2.44%
KMC Speciality Hosp.	133	1.95%
Blue Jet Healthcare	585.45	1.61%
Max Healthcare Inst.	1,129.05	1.30%
Syngene Internatl.	418.85	1.18%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Nectar Lifesciences	10.06	-3.45%
Fermenta Biotech	433	-2.48%
Themis Medicare	106.45	-1.48%
Wanbury	326.50	-1.42%
Bliss GVS Pharma	455	-1.30%

News about Top Pharma Companies in India

Jul, 2026

Anthem Biosciences informs about transcript of conference call

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Anthem Biosciences has informed that it enclosed the transcript of the earnings conference call held on July 22, 2026, at 11:30 AM, post announcement of Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. The said transcript is also available on website of the Company at https://anthembio.com/.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Novartis India - Quaterly Results

The June 2026 quarter revenue stood at Rs. 1038.10 millions, up 18.57% as compared to Rs. 875.50 millions during the corresponding quarter last year.A humble growth in net profit of 16.62% reported in the quarter ended June 2026 to Rs. 322.10 millions from Rs. 276.20 millions.The company reported a good operating profit of 436.50 millions compared to 378.50 millions of corresponding previous quarter.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	1038.10	875.50	18.57	1038.10	875.50	18.57	3543.30	3562.70	-0.54
Other Income	87.40	106.10	-17.62	87.40	106.10	-17.62	387.70	419.60	-7.60
PBIDT	436.50	378.50	15.32	436.50	378.50	15.32	1328.70	1333.80	-0.38
Interest	0.60	1.00	-40.00	0.60	1.00	-40.00	12.60	7.70	63.64
PBDT	435.90	377.50	15.47	435.90	377.50	15.47	1316.10	1326.10	-0.75
Depreciation	4.20	5.30	-20.75	4.20	5.30	-20.75	19.50	21.90	-10.96
PBT	431.70	372.20	15.99	431.70	372.20	15.99	1296.60	1304.20	-0.58
TAX	109.60	96.00	14.17	109.60	96.00	14.17	364.80	295.20	23.58
Deferred Tax	-5.00	0.00	0.00	-5.00	0.00	0.00	15.30	-4.40	-447.73
PAT	322.10	276.20	16.62	322.10	276.20	16.62	931.80	1009.00	-7.65
Equity	123.40	123.40	0.00	123.40	123.40	0.00	123.40	123.40	0.00
PBIDTM(%)	42.05	43.23	-2.74	42.05	43.23	-2.74	37.50	37.44	0.16

Jul, 2026

Rainbow Children’s Medicare informs about ESG rating

Pursuant to Regulation 30 of the SEBI Listing Regulations read with Schedule III thereto and the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Rainbow Children’s Medicare has informed that CRISIL ESG Rating & Analytics (‘CRISIL ESG’) has on a voluntary basis assessed the overall Environmental, Social and Governance (ESG) and has assigned an ESG rating of 61 and a Core ESG rating of 73, based on disclosures for FY 2025-26, on July 22, 2026. The ESG rating of 61 reflects an improvement from ‘Adequate’ to ‘Strong’ ESG rating assigned to the Company for FY 2024-25 and FY 2023-24. The Company has not engaged CRISIL ESG for ESG Ratings. CRISIL ESG has independently prepared the report based on data pertaining to FY 2025-26 for the Company available in public domain.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Rubicon Research soars on acquiring manufacturing facility in New Jersey, US

This site will focus on the company’s specialty and high value products as well as demand from US government departments

Jul, 2026

Rubicon Research acquires manufacturing facility in New Jersey, US

This site will focus on the company’s specialty and high value products as well as demand from US government departments

Jul, 2026

Wanbury informs about updates

Further to its letter dated 20th July, 2026, Wanbury has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility at Tanuku, West Godavari District, Andra Pradesh during the period from July 13, 2026 to July 17, 2026. At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time. The relevant disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/ 49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in Annexure - I.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Max Healthcare Institute Ltd.	1,08,476 Crore
2	Yatharth Hospital & Trauma Care Services Ltd.	8,132 Crore
3	3B Blackbio Dx Ltd.	1,112 Crore
4	Artemis Medicare Services Ltd.	4,408 Crore
5	Novartis India Ltd.	4,023 Crore
6	Jupiter Life Line Hospitals Ltd.	10,728 Crore
7	Jagsonpal Pharmaceuticals Ltd.	1,511 Crore
8	Neuland Laboratories Ltd.	24,345 Crore
9	Kwality Pharmaceuticals Ltd.	2,815 Crore
10	Rainbow Childrens Medicare Ltd.	15,076 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,813	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,017	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,385	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,600	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,714	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,283	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,017	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,543	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,283	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,385	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,570	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,106	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,813	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,147	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,106	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,988	4,73,509	41.25	5.67	23.65	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Anthem Biosciences informs about transcript of conference call

Novartis India - Quaterly Results

Rainbow Children’s Medicare informs about ESG rating

Rubicon Research soars on acquiring manufacturing facility in New Jersey, US

Rubicon Research acquires manufacturing facility in New Jersey, US

Wanbury informs about updates

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.